The recent landscape in the development of anti-fibriotic agents and prospects for future research

We have been developed anti-fibrotic agents initially focus on idiopathic pulmonary fibrosis (IPF) and also on progressive pulmonary fibrosis (PPF).

 I involved anti-fibrotic treatment with pirfenidone for IPF that significantly reduce the decline of vital capacity. Simultaneously, I developed nintedanib for IPF by the evaluation to reduce the decline of forced vital capacity (FVC). Furthermore, treatment with nintedanib in PPF other than IPF were evaluated as global trials.

 Recent landscape of the number of anti-fibrotic development increases over fifty candidates but few numbers of candidate remain in phase 3 trial. 

 I realized that there are many difficulties in scientifically verifying therapeutic interventions for orphan diseases. However, current IPF/PF-ILD treatment methods are not sufficient, and further elucidation of the etiology and development of treatments are necessary. It is still insufficient to scientifically elucidate the aging of cells and the total bodies, and we believe it is important to link the elucidation of the etiology with the development of treatments. 

In my talk, I will discuss the progress of anti-fibrotics development and the future aspects of efforts against aging.

3 Keywords: Anti-fibrotics, Progressive fibrosis and Aging